Biomarin Pharmaceutical Inc (BMRN)
Debt-to-assets ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 595,138 | 593,095 | 1,083,020 | 1,079,080 | 1,075,140 |
| Total assets | US$ in thousands | 6,988,940 | 6,841,600 | 6,375,070 | 6,004,770 | 5,848,020 |
| Debt-to-assets ratio | 0.09 | 0.09 | 0.17 | 0.18 | 0.18 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $595,138K ÷ $6,988,940K
= 0.09
The debt-to-assets ratio of Biomarin Pharmaceutical Inc has shown a consistent and favorable trend over the years, decreasing from 0.18 in both December 31, 2020, and December 31, 2021, to 0.17 in December 31, 2022, and further declining to 0.09 in both December 31, 2023, and December 31, 2024. This indicates that the company's level of debt in relation to its total assets has been decreasing steadily, suggesting a more conservative approach to financing its operations. A lower debt-to-assets ratio typically signifies less financial risk and greater stability, which can be viewed positively by investors and creditors. Biomarin Pharmaceutical Inc's ability to manage its debt effectively and maintain a strong financial position is reflected in this improving ratio. Further monitoring of this ratio will be crucial to assess the company's ongoing financial health and risk management strategies.
Peer comparison
Dec 31, 2024